| Income Statement | 2025-09-27 | 2025-06-28 | 2025-03-29 | 2024-09-28 |
|---|---|---|---|---|
| Net loss from continuing operations | - | - | - | -5,421 |
| Net income (loss) | 4,006 | 9,272 | -3,322 | -5,421 |
| Loss attributable to noncontrolling interest - continuing operations | - | - | - | -597 |
| (income) loss attributable to noncontrolling interest | 851 | 1,813 | -685 | - |
| Net income (loss) attributable to bioventus inc | 3,155 | 7,459 | -2,637 | -4,824 |
| Basic (in shares) | 66,924,682 | 66,500,433 | 66,008,683 | 65,258,427 |
| Diluted (in shares) | 68,837,797 | 68,536,759 | 66,008,683 | 65,258,427 |
| Loss per share of class a common stock, basic (in dollars per share) | 0.05 | 0.11 | -0.04 | -0.07 |
| Loss per share of class a common stock, diluted (in dollars per share) | 0.05 | 0.11 | -0.04 | -0.07 |
Bioventus Inc. (BVS)
Bioventus Inc. (BVS)